Clinical Trials
12 trialsNCT07466927 2026-03-12
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Fudan University
Phase 2 Not yet recruiting
NCT05275777 2025-07-25
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT06102824 2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT04450706 2024-10-28
FORESEE
University of Utah
Phase NA Completed
NCT03575065 2024-10-26
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
BeiGene
Phase 2 Completed
NCT04942054 2023-05-22
A Study in Patients With Advanced Breast Cancer
Sun Pharma Advanced Research Company Limited
Phase 1 Terminated
NCT04848454 2022-10-18
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
Peking University First Hospital
Phase 2 Unknown
NCT05334147 2022-04-19
ALOT-BC1
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT05263882 2022-03-03
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT04576143 2021-08-12
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Recruiting
NCT04624711 2021-05-21
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04498793 2020-09-03
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown